Endocrine

*SoonerCare members with Medicare DO NOT need a Prior Authorization*

• darbepoetin (Aranesp®)
• epoetin (Epogen®)
• epoetin (Procrit®)

PA Criteria:

FDA approved indication for specific products.

• Treatment of Anemia of Chronic Renal Failure Patients (ESAs are included in the dialysis payment if patient is on ANY form of dialysis)
• Treatment of Anemia of Zidovudine-treated HIV-infected Patients
• Treatment of Anemia of Cancer Patients on Chemotherapy

• Myelosuppressive Chemotherapy-induced Anemia (Hb 8-10 g/dl) Non-Curative

• Reduction of Allogeneic Blood Transfusion in Surgery Patients

Most recent Hb levels (and date obtained) should be included on petition. Each approval will be for 16 weeks in duration. Authorization can be granted for up to 8 weeks following the final dose of myelosuppressive chemotherapy in a chemotherapy regimen. Authorization for surgery patients will be for a maximum of 4 weeks.Continuation Criteria:

• Continue dose if Hb is ≤11.0 g/dL.
• If Hb is increasing and approaching 11.0 g/dL then reduce dose.
• If more than 1 g/dL increase (but Hb not greater than upper limits listed below) has occurred in a 2 week period reduce dose by 25 to 50%.

Discontinuation Criteria

• Discontinue treatment if Hb is at or above 11.0 g/dL.
• If a minimum increase of 1 g/dL has not been achieved after initial 8 weeks of therapy for anemia associated with chemotherapy and 12 weeks of therapy for ESRD.

Reinitiation Criteria:

• If Hb decreases to ≤10 g/dL then therapy may be reinitiated at 25 to 50% of the prior dose.

Suprax® (Cefixime), Cedax® (Ceftibuten), and Spectracef® (Cefditoren) Approval Criteria:

• Indicated diagnosis or infection known to be susceptible to requested agent; AND
• A patient-specific, clinically significant reason why the member cannot use cephalexin and cefdinir, or other cost effective therapeutic equivalent medication(s).

• Genotropin®

• Humatrope®
• Norditropin®
• Norditropin Nordiflex®
• Nutropin®
• Nutropin AQ®
• Omnitrope®
• Saizen®
• Serostim®
• Tev-Tropin®
• Zorbtive®

PA Criteria:

• An FDA approved diagnosis as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism; AND
  • Natpara® is not FDA approved for hypoparathyroidism caused by calcium-sensing receptor mutations.
  • Natpara® is not FDA approved for hypoparathyroidism due to acute post-surgery.
• Magnesium deficiency must be ruled out; AND
• Member must have pretreatment serum calcium above 7.5mg/dL before starting Natpara®; AND
• Prescriber must verify the member has sufficient 25-hydroxyvitamin D level per standard of care; AND
• Member must be unable to be adequately well-controlled on calcium supplements and active forms of vitamin D alone; AND
• Health care provider and dispensing pharmacy must be certified through the Natpara® Risk Evaluation and Mitigation Strategies (REMS) Program; AND
• A quantity limit of two cartridges (each package contains two 14-day cartridges) per 28 days will apply. The maximum covered dose will be 100mcg per day.

Afrezza® (Insulin Human) Inhalation Powder Approval Criteria:

• An FDA approved diagnosis of diabetes mellitus; and
• Member must be 18 years of age or older; and
• A patient-specific, clinically significant reason why other rapid-acting injectable insulins are not appropriate; and
• For the indication of type 1 diabetes, the member must use Afrezza® with a long-acting insulin; and
• The member must not smoke or have chronic lung disease such as asthma or chronic obstructive pulmonary disease (COPD).

Toujeo® (Insulin Glargine) Approval Criteria:

• An FDA approved diagnosis of diabetes mellitus; and
• A patient-specific, clinically significant reason why member cannot use Lantus® (insulin glargine), and member must be using a minimum of 100 units of Lantus® (insulin glargine) per injection.

PA Criteria for oral diabetic medications:

• To qualify for a tier 2 medication, the member must have a trial of a tier 1 medication (must include a trial of metformin titrated up to maximum dose), or a clinical reason why a tier 1 medication is not appropriate.
• For initiation with dual or triple therapy, additional tier 2 medications can be approved based on current AACE or ADA guidelines.
• To qualify for a tier 3 medication, the member must have tried a tier 2 medication in the same category and have a documented clinical reason why the tier 2 medication is not appropriate.
• To qualify for a Special Prior Authorization medication, the member must be currently stabilized on the requested product or have attempted at least 3 other categories of tier 2 or tier 3 medications, or have a documented clinical reason why the requested product is necessary for the member.

Biaguanides

• metformin (Glucophage®)
• metformin SR (Glucophage XR®)
• metformin-glyburide (Glucovance®)
• metformin-glipizide (Metaglip®)

Sulfonylureas

• glyburide (Diabeta®)
• glyburide micronized (Micronase®)
• glipizide (Glucotrol®)
• glipizide SR (Glucotrol XL®)

Alpha-Glucosidase Inhibitors

• acarbose (Precose®)

Glinides

• nateglinide (starlix®)
• repaglinide (Prandin®)

Thiazolidinediones

• pioglitazone (Actos®)

DDP-4 Inhibitors

• saxagliptin (Onglyza®)
• saxagliptin-metformin (Kombiglyze®)
• sitagliptin (Januvia®)
• stiagliptin-metformin (Janumet®)
• sitagliptin-metformin ER (Janumet XR®)

Glinides

• repaglinide-metformin (Prandimet®)

GLP-1 Agonists

• liraglutide (Victoza®)
• exenatide (Byetta®)
• exenatide (Bydureon®)

DDP-4 Inhibitors

• alogliptin-metformin (Kazano®)
• alogliptin (Nesina®)
• alogliptin-pioglitazone (Oseni®)
• linagliptin (Tradjenta®)
• linagliptin-metformin (Jentadueto^TM)

Thiazolidinediones

• rosiglitazone (Avandia®)
• pioglitazone-metformin (Actoplus Met®, Actoplus Met XR®)
• pioglitazone-glimepiride (Duetact®)
• rosiglitazone-metformin (Avandamet®)
• rosiglitazone-glimepiride (Avandaryl®)

Alpha-Glucosidase Inhibitors

• miglitol (Glyset®)

SGLT2 inhibitor

• canagliflozin (Invokana®)
• canagliflozin/metformin (Invokamet^TM )
• dapagliflozin (Farxiga ®)
• dapagliflozin-metformin (Xigduo™ XR)
• empagliflozin (Jardiance®)

Dopamine Agonist

• bromocriptine (Cycloset®)

SGLT-2/DPP-4 Inhibitor

• empagliflozin/linagliptin (Glyxambi®)

GLP-1 Agonists

• albiglutide (Tanzeum™)
• dulaglutide (Trulicity®)

Biaguanides

• metformin solution (Riomet®)
• metformin long acting (Fortamet®, Glumetza®)

Amylinomimetic

• pramlintide (Symlin®)

*Brand products are subject to the Brand Name Override where generics are available

Testosterone replacement products Prior Authorization Criteria

Consideration will be based on both of the following criteria:

• An FDA approved diagnosis of:
  • Testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome, orchidectomy/orchiectomy; OR
  • Idiopathic gonadotropin or luteinizing-hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation; OR
  • Delayed puberty; OR
  • Advanced inoperable metastatic mammary cancer in females 1 to 5 years postmenopausal, or premenopausal women with breast cancer benefitting from oophorectomy and have been determined to have a hormone-responsive tumor; AND
• Must include two labs showing pre-medication, morning testosterone(total testosterone) levels below 300ng/dL; AND
• Must include one lab showing abnormal gonadotropins and/or other information necessary to demonstrate diagnosis; OR
• Testosterone and gonadotropin labs are not required for authorization of testosterone therapy if documentation is provided for established hypothalamic pituitary or gonadal disease or if the pituitary gland or testes has/have been removed.

Testosterone replacement products Tier-2 Prior Authorization Criteria:

• All diagnoses and laboratory requirements listed above must be met; AND
• A trial of at least two Tier-1 products (must include at least one injectable and one topical formulation) at least 12 weeks in duration; OR
• A patient-specific, clinically significant reason why member cannot use all available Tier-1 medications; OR
• Prior stabilization on a Tier-2 medication (within the past 180 days).
• Approvals will be for the duration of one year.

Testosterone replacement products Special Prior Authorization Criteria Consideration will be based on the following criteria:

• All diagnoses and laboratory requirements listed above must be met; AND
• A patient-specific, clinically significant reason why member cannot use all other available formulations of testosterone.
• Approvals will be for the duration of one year.

*Please note that approval will be for one year.

• methyltestosterone powder
• testosterone cypionate injection (Depo-Testosterone®)
• testosterone enanthate injection
• testosterone topical gel (Androgel®)

• testosterone patch (Androderm®)
• testosterone topical gel (Fortesta®)
• testosterone topical solution (Axiron®)
• testosterone nasal gel (Natesto™)
• testosterone undecanoate injection (Aveed®)
• testosterone topical gel (Testim®, Vogelxo™)

• fluoxymesterone oral tablet (Androxy®)
• methyltestosterone oral tablet/capsule (Android®, Methitest®, Testred®)
• testosterone buccal tablet (Striant®)
• testosterone (Testopel Pellets®)

• romiplostim (Nplate®)
• plerixafor (Mozobil®)

PA Criteria:

• Documented history of previous singleton spontaneous preterm delivery (SPTD) prior to 37 weeks gestation; and
• Current singleton pregnancy; and
• Gestational age between 16 weeks, 0 days and 20 weeks, 6 days of gestation.
• Authorizations will be for once a week administration by a healthcare professional through 36 weeks, 6 days of gestation.